Because we didn’t have the right data set to come out from under the radar. If we had come out back in 2021 we would have burnt all our bridges with pharma and overseas investors and would have no future. People seem to forget that we had to entirely pivot the company at the end of 2021 to build on the cardioprotection discovery.
If you want to critique something ask why it took from 2019 when I first had the hypothesis that cardioprotection was possible until 2021 before this was investigated or why it took until 2022 for RC220 to be developed despite me knowing this was critical and starting on it in early 2020.
Ann: Race Strategic Update August 2023, page-174
-
- There are more pages in this discussion • 419 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
0.020(1.12%) |
Mkt cap ! $309.3M | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.84 | $1.80 | $105.9K | 58.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1316 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 4377 | 1 |
View Market Depth
| Last trade - 12.14pm 01/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |